Literature DB >> 17067269

Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.

Soumi Gupta1, Fengmin Zhou, Catherine E Greer, Harold Legg, Tony Tang, Paul Luciw, Jan zur Megede, Susan W Barnett, John J Donnelly, Derek T O'Hagan, John M Polo, Michael Vajdy.   

Abstract

Mucosal and systemic transmission of HIV is prevalent. Therefore, mucosal followed by parenteral immunizations with chimeric vs. complete alphavirus-based replicon particles, encoding an HIV envelope glycoprotein, were tested. Female rhesus macaques were immunized intranasally and then intramuscularly. Following the immunizations, enhanced mucosal and systemic antibody responses were detected with the chimeric compared to the complete replicon particles. Although similar proportions of the same peripheral blood monocyte lineage target cells were infected with the chimeric vs. the complete replicon particles, the latter resulted in enhanced expression of the gene of interest, suggesting a possible mechanism of the enhanced immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17067269     DOI: 10.1089/aid.2006.22.993

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

Review 1.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

2.  Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Authors:  Elizabeth A Reap; Sergey A Dryga; John Morris; Bryan Rivers; Pamela K Norberg; Robert A Olmsted; Jeffrey D Chulay
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

3.  Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Authors:  Yasushi Uematsu; Michael Vajdy; Ying Lian; Silvia Perri; Catherine E Greer; Harold S Legg; Grazia Galli; Giulietta Saletti; Gillis R Otten; Rino Rappuoli; Susan W Barnett; John M Polo
Journal:  Clin Vaccine Immunol       Date:  2012-05-23

4.  Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Authors:  Susan W Barnett; Brian Burke; Yide Sun; Elaine Kan; Harold Legg; Ying Lian; Kristen Bost; Fengmin Zhou; Amanda Goodsell; Jan Zur Megede; John Polo; John Donnelly; Jeffrey Ulmer; Gillis R Otten; Christopher J Miller; Michael Vajdy; Indresh K Srivastava
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

5.  Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development.

Authors:  Tingting Yuan; Jingjing Li; Yu Zhang; Yanping Wang; Emily Streaker; Dimiter S Dimitrov; Mei-Yun Zhang
Journal:  Vaccine       Date:  2011-07-30       Impact factor: 3.641

6.  Viral vectors for vaccine applications.

Authors:  Youngjoo Choi; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

7.  A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles.

Authors:  Chien-Hsiung Pan; Catherine E Greer; Debra Hauer; Harold S Legg; Eun-Young Lee; M Jeff Bergen; Brandyn Lau; Robert J Adams; John M Polo; Diane E Griffin
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

8.  Identification of residues outside of the receptor binding domain that influence the infectivity and tropism of porcine endogenous retrovirus.

Authors:  Takele Argaw; Mariel Figueroa; Daniel R Salomon; Carolyn A Wilson
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

Review 9.  Replicating and non-replicating viral vectors for vaccine development.

Authors:  Marjorie Robert-Guroff
Journal:  Curr Opin Biotechnol       Date:  2007-12-11       Impact factor: 9.740

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.